Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs.

Google DeepMind's spinoff Isomorphic Labs is set to begin human trials of a drug desinged completely by Artificial Intelligence.

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is ...

Isomorphic Labs, the AI -powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI.

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...

In national conversations, Crystal Mountain may fly under the radar sometimes, but at this ski resort, you’ll find lines and runs as good as any other destination on the continent, provided you know ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 million.

Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling breakthroughs.

Isomorphic Labs is headquartered in London and has office locations in Lausanne, Switzerland and Cambridge, Massachusetts. For more information, go to and follow us on LinkedIn and X .

Precision oncology leader joins world-class team as company enters next phase of translating AI-driven drug discovery into life-changing medicines. As Chief Medical Officer, Dr. Wolf will bring ...

About Dr. Ben Wolf, Chief Medical Officer, Isomorphic Labs Dr. Wolf brings nearly 20 years of biopharmaceutical experience to Isomorphic Labs, with particular expertise in precision oncology and ...